AbbVie Lowers Full-Year Profit Guidance, Investor Disappointment Triggers Stock Sell-Off
AbbVie (ABBV) reported Q2 revenue near $17B, up over 10% YoY, and adjusted EPS of $3.65, missing the $3.71 consensus. Revenue slightly beat estimates. The company also cut full-year 2026 EPS guidance to $13.87-$14.07 from $13.91-$14.11, below $14.12 consensus, prompting shares to fall nearly 3%.
How this was made
The 30-second read
Why it matters
The guidance reduction is framed as the decisive driver of the stock’s short-term pullback, despite a generally positive revenue and dividend backdrop.
Market read
Traders should focus on the revised EPS range versus consensus and how investors weigh it against segment growth and dividend stability.
What to watch
Oncology revenue decline and the acquisition-related guidance adjustment could be temporary; traders may need to separate underlying demand trends from accounting or integration effects.
Background
AbbVie reported Q2 results with revenue growth and mixed segment performance, then revised full-year EPS outlook downward.
Ticker impact
AbbVie cut full-year 2026 EPS guidance to $13.87 to $14.07 after Q2, driving a near 3% sell-off.
Near-term downside pressure likely persists until investors re-anchor on the revised EPS range and segment trends.
The article attributes the Friday pullback directly to the downward full-year profit guidance revision, with explicit EPS range and consensus comparison.
Market effects
Signals pharma earnings sensitivity to guidance revisions even when revenue growth and dividend narratives remain intact.
Primarily US large-cap pharma sentiment, with potential spillover to dividend-focused healthcare peers.
Limited global read-through beyond large-cap pharma investors tracking guidance credibility.
Counterpoint
Despite the EPS miss and guidance cut, the article highlights strong immunology and neuroscience growth plus dividend durability, which may support dip-buying.
Key entities
- companyAbbVie
Cut full-year 2026 EPS guidance to $13.87 to $14.07 after Q2, below prior forecast and consensus.
- productSkyrizi
Immunology category growth cited, with Skyrizi delivering solid performance.
- productRinvoq
Mentioned as a growth driver alongside Skyrizi for future sales.
- acquisitionApogee Therapeutics
Acquisition cited as the reason AbbVie adjusted its earnings outlook.
